Cilostazol

Active ingredient: Cilostazol

In short: Cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance.

Forms & strengthsCilostazol Tablets, USP are available containing 50 mg or 100 mg of cilostazol USP. The 50 mg tablets are white to off-white, round, flat bevel edged tablets debossed with ‘CI’ on one side and ‘50’ on other side. …
LabelAurobindo Pharma Limited
Label updatedOct 22, 2026

What is Cilostazol used for?

Cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance.

⚠ Boxed warning (FDA's strongest warning)

Cilostazol tablets are contraindicated in patients with heart failure of any severity. Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV heart failure .

Cilostazol dosage

The recommended dosage of cilostazol tablets is 100 mg twice daily taken at least half an hour before or two hours after breakfast and dinner.

Patients may respond as early as 2 to 4 weeks after the initiation of therapy, but treatment for up to 12 weeks may be needed before a beneficial effect is experienced. If symptoms are unimproved after 3 months, discontinue cilostazol tablets.

Reduce dose to 50 mg twice daily when coadministered with strong or moderate inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, erythromycin, and diltiazem) or inhibitors of CYP2C19 (e.g., ticlopidine, fluconazole, and omeprazole) .

How to take Cilostazol — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information)

Advise the patient:

to take cilostazol tablets at least one-half hour before or two hours after food.

to discuss with their doctor before taking any CYP3A4 or CYP2C19 inhibitors (e.g., omeprazole).

that the beneficial effects of cilostazol tablets on the symptoms of intermittent claudication may not be immediate. Although the patient may experience benefit in 2 to 4 weeks after initiation of therapy, treatment for up to 12 weeks may be required before a beneficial effect is experienced. Discontinue cilostazol tablets if symptoms do not improve after 3 months.

Distributed by:

Aurobindo Pharma USA, Inc.

279 Princeton-Hightstown Road East Windsor, NJ 08520

Manufactured by:

Aurovitas Pharma Taizhou Co.,Ltd.

No.196, Xiangtai Road, China Medical City, Taizhou, Jiangsu 225300, China License Number: 苏20210041

Issued: September 2026

Warnings & precautions

Do not take this medicine if: Cilostazol tablets are contraindicated in patients with:

Heart failure of any severity: Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV heart failure.

Hypersensitivity to cilostazol or any components of cilostazol tablets (e.g., anaphylaxis, angioedema)

Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension. The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm. Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.

Left ventricular outflow tract obstruction has been reported in patients with sigmoid shaped interventricular septum. Monitor patients for the development of a new systolic murmur or cardiac symptoms after starting cilostazol.

Cases of thrombocytopenia or leukopenia progressing to agranulocytosis when cilostazol tablets were not immediately discontinued have been reported. Agranulocytosis is reversible on discontinuation of cilostazol tablets. Monitor platelets and white blood cell counts periodically.

Cilostazol tablets inhibit platelet aggregation in a reversible manner. Cilostazol tablets have not been studied in patients with hemostatic disorders or active pathologic bleeding. Avoid use of cilostazol tablets in these patients.

Cilostazol side effects

The following adverse reactions are discussed in greater detail in other sections of the labeling:

Patients with Heart Failure

Tachycardia

Left Ventricular Outflow Tract Obstruction

Hematologic Adverse Reactions

Hemostatic Disorders or Active Pathologic Bleeding

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse reactions were assessed in eight placebo-controlled clinical trials involving patients exposed to either 50 or 100 mg twice daily cilostazol tablets (n = 1301) or placebo (n = 973), with a median treatment duration of 127 days for patients on cilostazol tablets and 134 days for patients on placebo.

The most frequent adverse reaction resulting in discontinuation of therapy in more than 3% of patients treated with cilostazol tablets was headache [50 mg twice daily (1.3%), 100 mg twice daily (3.5%) and placebo (0.3%)]. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol tablets (all doses) versus 0.1% for placebo.

The most common adverse reactions, occurring in at least 2% of patients treated with cilostazol tablets 50 or 100 mg twice daily, are shown in Table 1. …

Drug interactions

Inhibitors of CYP3A4:

Coadministration of strong (e.g., ketoconazole) and moderate (e.g., erythromycin, diltiazem and grapefruit juice) CYP3A4 inhibitors can increase exposure to cilostazol tablets. Reduce cilostazol tablets dose to 50 mg twice daily when coadministered with strong or moderate inhibitors of CYP3A4 .

Inhibitors of CYP2C19:

Coadministration with CYP2C19 inhibitors (e.g., omeprazole) increases systemic exposure of cilostazol tablets active metabolites. Reduce cilostazol tablets dose to 50 mg twice daily when coadministered with strong or moderate inhibitors of CYP2C19 .

About this medicine

Cilostazol, USP is a quinolinone derivative that inhibits cellular phosphodiesterase (more specific for phosphodiesterase III). The molecular formula of cilostazol is C20H27N5O2, and its molecular weight is 369.46. Cilostazol is 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone, CAS-73963-72-1.

The structural formula is:

Cilostazol, USP occurs as white to off-white crystals that are freely soluble in chloroform, slightly soluble in methanol and alcohol, and practically insoluble in water.

Cilostazol tablets, USP for oral administration are available in 50 mg and 100 mg white to off-white, round, flat bevel edged debossed tablets. Each tablet, in addition to the active ingredient, contains the following inactive ingredients: corn starch, croscarmellose sodium, hypromellose, magnesium stearate and microcrystalline cellulose.

Meets USP Dissolution Test 2. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 7c841eed-a98f-43c3-baaf-bf5502207a69. Read the full official label on DailyMed.